Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-World Study of FOLFOX Combined With Panitumumab N01 Versus Cetuximab as First-Line Treatment for RAS Wild-Type Metastatic Colorectal Cancer

NCT07917429 is registered in ClinicalTrials.gov with Fujian Medical University Union Hospital as lead sponsor.

NCT NCT07917429 Not yet recruiting Observational 610 participants (estimated) Started 2027 1 site

Follow this trial by email Email me the PDF

Get the NCT07917429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started January 2027. Observational study, 610 participants (estimated). Lead sponsor Fujian Medical University Union Hospital; China. Primary measures: overall survival; Incremental Cost-Utility Ratio (ICUR).

How it compares

1,394 similar trials: same condition (Colorectal Neoplasms) and phase

Enrollment

This trial
610
Middle half
80 to 852
Median
250
Trials with a value
1,384

Months from start to completion

This trial
41
Middle half
20 to 66
Median
36.5
Trials with a value
1,362

Sites

This trial
1
Middle half
1 to 2
Median
1
Trials with a value
1,237
Posted results or a linked paper 35% 487 of 1,394 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-World Study of FOLFOX Combined With Panitumumab N01 Versus Cetuximab as First-Line Treatment for RAS Wild-Type Metastatic Colorectal Cancer
Lead sponsor
Fujian Medical University Union Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
June 1, 2030
Enrollment
610 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Colorectal Neoplasms

Registry terms: colorectal cancer metastatic

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Observational
Sites
1
Countries
China
Lead sponsor
Fujian Medical University Union Hospital

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
Panitumumab N01 Panitumumab N01
Show registry wording

Panitumumab N01 plus FOLFOX

Cetuximab Cetuximab (EGFR inhibitor)
Show registry wording

Cetuximab or Cetuximab N01 plus FOLFOX

Primary endpoints

Registered primary outcome measures; 2 primary.

Registered primary endpoints
Measure Time frame
overall survival From date of first diagnosis of RAS wild-type metastatic colorectal cancer until date of death from any cause, assessed up to 30 months
Show registry wording

Time from the index-date (initial diagnosis of RAS wild-type mCRC) to death from any cause. Patients alive or lost-to-follow-up will be censored at the date of last valid follow-up.

Incremental Cost-Utility Ratio (ICUR) From date of treatment initiation until date of study completion, death, or loss to follow-up, whichever comes first, assessed up to 30 months
Show registry wording

Ratio of incremental direct medical costs versus incremental quality-adjusted life-years (QALYs) between the Panitumumab N01 arm and the cetuximab/cetuximab N01 arm; unit: CNY per QALY. Only costs generated after Panitumumab N01 is listed for national medical reimbursement are included.

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • CETUXIMAB 1 Orange Book patent
    • US 6217866; expires February 12, 2018; assignee Rhone-Poulenc Rorer International (Holdings), Inc.

Lead sponsor's other trials

Fujian Medical University Union Hospital, most recent start first.

Similar trials

Same condition (Colorectal Neoplasms) and phase, most recent start first.